Oppenheimer & Co
TRVI icon

Oppenheimer & Co’s Trevi Therapeutics TRVI Stock Holding History

Oppenheimer & Co’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.44M Buy
100,696
+925
+0.9% +$15.9K 0.02% 762
2026
Q2 		$1.86M Sell
99,771
-256
-0.3% -$3.72K 0.02% 665
2026
Q1 		$1.19M Sell
100,027
-671
-0.7% -$7.51K 0.01% 792
2025
Q4 		$1.26M Buy
100,698
+2,030
+2% +$23.5K 0.02% 709
2025
Q3 		$903K Sell
98,668
-1,157
-1% -$8.68K 0.01% 945
2025
Q2 		$546K Sell
99,825
-612
-0.6% -$3.81K 0.01% 1108
2025
Q1 		$632K Buy
100,437
+19,034
+23% +$90.8K 0.01% 997
2024
Q4 		$335K Sell
81,403
-544
-0.7% -$1.74K 0.01% 1212
2024
Q3 		$274K Buy
81,947
+21,128
+35% +$62.8K ﹤0.01% 1285
2024
Q2 		$181K Buy
60,819
+404
+0.7% +$1.12K ﹤0.01% 1349
2024
Q1 		$208K Buy
+60,415
New +$135K ﹤0.01% 1328

Other funds holding TRVI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Oppenheimer & Co's TRVI Position: Q3 2026 in Review

Oppenheimer & Co increased its Trevi Therapeutics (TRVI) stake by 0.93% in Q3 2026, buying an estimated $15.9K and bringing the position to 100,696 shares worth $1.44M. The position accounts for 0.02% of the portfolio, ranked #762.

Oppenheimer & Co first reported a position in TRVI in Q1 2024 and has held it in 11 quarters since. The position peaked at $1.86M in Q2 2026. 152 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Oppenheimer & Co held 100,696 shares of Trevi Therapeutics worth $1.44M as of Q3 2026.
  • Oppenheimer & Co bought 925 Trevi Therapeutics shares in Q3 2026, an estimated $15.9K.
  • Trevi Therapeutics made up 0.02% of Oppenheimer & Co's portfolio in Q3 2026, its #762 holding.
  • Oppenheimer & Co first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • Oppenheimer & Co's Trevi Therapeutics position peaked at $1.86M in Q2 2026.
  • 152 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.